Thermo Fisher Scientific Launches Closed System for the manufacturing of Cell Therapies
Thermo Fisher Scientific has launched Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed-cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system facilitates workflows from research through to good manufacturing practice (GMP) clinical development and commercial manufacturing.
With over 650 clinical trials underway globally for cell therapy and cell-based immune-oncology, there are yet few cell therapies in development that become commercially available due to several factors, safety and efficacy requirements, difficulties in transferring research protocols to manufacturing processes, lack of scalability of these therapies, high cost of facilities, labor and equipment, and complexity of the processes involved.
The CTS Rotea, a multifunctional and highly flexible system can easily integrate into existing workflows, process low- to mid-range input volumes, and deliver low output volumes.
SparingVision raises $52.5 million to develop mutation-agnostic gene therapy
SparingVision has raised $52.5 million to develop its mutation-agnostic gene therapy treatment for retinitis pigmentosa (RP). SparingVision aims to fund clinical trials of an AAV gene therapy that could stop vision deterioration in the 2 million RP patients, aiming to go after the whole RP
With GMP manufacturing almost done and IND-enabling studies underway, the funding will enable SparingVision to move into a clinical trial to assess the safety of its candidate next year. Once SparingVision has safety data, it will run an efficacy trial using the series A funds.
The potential to take a mutation-agnostic RP gene therapy to clinical proof of concept has attracted a diverse group of investors. VC 4BIO Capital led the round with UPMC Enterprises, and UPMC. Jeito Capital, Ysios Capital, Bpifrance, and Foundation Fighting Blindness also participated.
Roche signs deal with Dyno Therapeutics for AAV Gene Therapy.
Dyno Therapeutics has recently signed a deal with Roche to develop next-generation AAV (adeno-associated virus) gene therapy vectors for central nervous system (CNS) diseases and liver-directed therapies.
Under the agreement, Dyno will be in charge of the design of the novel AAV capsids with improved functional properties while Roche will be in charge of all the pre-clinical, clinical, and commercialization activities for the product.
Dyno could expect more than $1.8 billion of payments although the amount of upfront payment was undisclosed.